ABEO
Abeona Therapeutics Inc
NASDAQ: ABEO · HEALTHCARE · BIOTECHNOLOGY
$5.42
-1.19% today
Updated 2026-09-11
Market cap
$331.10M
P/E ratio
—
P/S ratio
12.97x
EPS (TTM)
$-1.20
Dividend yield
—
52W range
$4 – $8
Volume
1.4M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A7.5
Quality
B+4.0
Profitability
C5.0
Valuation
C+6/9
Piotroski F-Score
Moderate
-1.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$18.86
+248.29%
12-Month target
$4.42
-18.37%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 45.63% — strong efficiency
+ Revenue growth 2,745.00% QoQ
+ Debt/equity 0.16x — low leverage
Risks
- Altman Z -1.04 — distress zone
- Thin margins at -246.40%
- Negative free cash flow $-17.98M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.41M | $3.50M | $0.00 | $5.82M | $25.52M |
| Net income | $-39.70M | $-54.19M | $-63.73M | $71.18M | $-20.19M |
| EPS | — | — | — | — | $-1.20 |
| Free cash flow | $-43.61M | $-37.34M | $-58.46M | $-84.30M | $-17.98M |
| Profit margin | -2,807.36% | -1,548.23% | — | 1,223.08% | -246.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-21 | VAZZANO, JOSEPH WALTER | Sale | 1,478 | $6.53 |
| 2026-07-09 | VAZZANO, JOSEPH WALTER | Sale | 24,880 | $6.96 |
| 2026-07-09 | VASANTHAVADA, MADHAV | Sale | 12,606 | $6.96 |
Peer comparison
Smart narrative
Abeona Therapeutics Inc trades at $5.42. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -1.04, it sits in the distress. TTM revenue stands at $25.52M. with profit margins at -246.40%.
Frequently asked questions
What is Abeona Therapeutics Inc's stock price?
Abeona Therapeutics Inc (ABEO) trades at $5.42, on a P/S of 13.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Abeona Therapeutics Inc overvalued?
Abeona Therapeutics Inc carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Abeona Therapeutics Inc (ABEO)?
The 12-month analyst consensus target is $18.86, about 248.3% above the current $5.42. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Abeona Therapeutics Inc's revenue?
Abeona Therapeutics Inc's trailing twelve-month revenue is $25.52M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Abeona Therapeutics Inc's Altman Z-Score is -1.04, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.97x
ROE45.63%
Beta1.32
50D MA$6.43
200D MA$5.51
Shares out0.06B
Float0.04B
Short ratio—
Avg volume1.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—